TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity to electrically induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Engagement in care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight loss from birth to 24 h postbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients who maintained virologic suppression at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postoperative sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Health score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of group decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost for charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative abundance of palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting palmitoylcarnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prolonged diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Persuasion scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reassurance scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anterior-posterior diameters of the mesencephalon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of low-density lipoprotein to high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiotoxicity-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of any adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Median time-to-onset of any AEs
Endpoint domain: Adverse events/effects
Primary endpoint: ADAS-Cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: visual analog scale pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotoxin activity in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum HDL-cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum LDL-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fat mass (FM) and fat-free mass (FFM) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pelvic relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure to NES and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mobility-related scanning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thigh IMAT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lean tissue loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free-from-progression period (FFPP)
Endpoint domain: Mortality/survival
Primary endpoint: Need for postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative maximal inspiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resting muscle PCr concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Torque production during maximal intermittent knee extensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful removal of cerumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients meeting PASI 75 at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ipsilateral microembolic signals reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rate of new ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: in-stent restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Emotions improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentrations of ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of AR-C124910XX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ticagrelor tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six minutes walk test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen consumption at anaerobic threshold (VO(2) @ AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen consumption (VO(2) max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C/P ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically meaningful improvement in Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone Ultrasound Attenuation (BUA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velocity of Sound (VOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Wellness score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adrenal glucocorticoid responsiveness suppression
Endpoint domain: Adverse events/effects
Primary endpoint: Mean VAS scores during SWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rate of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inability to work (days longer)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of physical problems (SF-36 data)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Excretion of fecal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Expression of HLA-DR, B7-1, and B7-2 on bile ducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean marginal bone level (MBL) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of months with 0 SSIs per center
Endpoint domain: Adverse events/effects
Primary endpoint: Correct timing of preoperative prophylactic antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients without therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage with HIV RNA <50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: large-for-date infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: color stability (ΔE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported PPE use when caring for patients with suspected pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure Control Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Receptive syringe sharing
Endpoint domain: Adverse events/effects
Primary endpoint: Distributive syringe sharing
Endpoint domain: Adverse events/effects
Primary endpoint: Syringe-mediated drug sharing
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration‐time curve (AUC(infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Brigance toddler screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the TCQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in angle of the longitudinal axis of the condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion of recommended baseline laboratory monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain visual analog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill Pain Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic consumption at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of narcotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ ATP release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ease of submucosal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of snaring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-procedural hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: median treatment outcome score at 4 hours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median change in mean symptom complex severity score at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estimated time to significant improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Successful treatment rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence and severity of side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Complete anesthesia achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postnatal changes in phospholipid 22:6n‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postnatal changes in phospholipid 20:4n‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cockroaches trapped
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 of less than 80% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal metformin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent dentifrice ingested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of glands activated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression versus regression of values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients successfully treated after 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients benzodiazepine free after 2 or 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of dental sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: VEGF‐C serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGF‐β serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL‐6 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL‐10 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Recovery of barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Expired concentration and MAC of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery times (autonomous respiration, tracheo-tube removal, eye-opening, voluntary motion, orientation force, operating room departure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benzodiazepine prescribing rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Achievement of KDOQI serum phosphate targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid stenosis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral artery stenosis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalent cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: keo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose tolerance (glucose AUC of OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time-to-recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Speed of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-operation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: d-dimer increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: t-PA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LA mean voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA activation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common classification by quartile between HUI2 and HUI3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutrophil function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pain scores with motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported voice quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interrater agreement of participants' stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAP increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TH increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUCt of pitavastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of PE in eyes with BRVO and CRVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of glaucoma in eyes with BRVO and CRVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AMD severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: illicit-drug use days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of hospitalization for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Thickness of the transverse abdominal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of the transverse abdominal muscle contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean INR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of dosage adjustments required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression time to total oral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systemic fasiglifam exposure (Cmax and AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of thrombin generation lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of thrombin generation peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of thrombin generation constant velocity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local progression-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean annual expansion rate of AAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ischemic territory that had undergone reperfusion at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early neurologic improvement at 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional independence at 90 days (modified Rankin scale score of 0 to 2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pivot shift grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak knee-flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in health-related quality of life (IBSQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in days lost from social/leisure activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Endothelium-dependent vasodilation (EDVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median villous height/crypt depth (Vh/Cd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraepithelial lymphocyte (IEL) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: predicted adult height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chance of walking 10,000 steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention and motor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in home limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean energy requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy mean scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perfect performance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing in Noise Test scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abbreviated Profile of Hearing Aid Benefit scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delayed recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incremental area under the insulin curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of MRSA in the population
Endpoint domain: Mortality/survival
Primary endpoint: Overall symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up-regulation of CD203c in basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean RLU of surfaces treated with IOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RODAC colony counts from IOS-treated sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes